MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients with Active Rheumatoid Arthritis

The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study. Patients with active rheumatoid arthritis treated with oral methotrexate up to 25mg weekly will be randomised in 50:50 fashion to receive 25mg oral vs subcutaneous methotrexate for the period of 24 weeks. In regular visits, patient reported outcomes, clinical disease activity, therapy adherence and diverse established and exploratory biomarkers will be assessed.

NCT Number	NCT06649136
Lead Sponsor	Medical University of Vienna Collaborators: Leiden University Medical Center, Karolinska Institutet, Queen Mary University of London, Diakonhjemmet Hospital AS
Conditions	Rheumatoid Arthritis
Enrollment	182 participants
Start Date	2024-08-12
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2024-10-18